Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma (NASDAQ: STRO) is a clinical-stage biopharmaceutical company pioneering next-generation oncology therapeutics through its proprietary cell-free XpressCF® platform. This page provides centralized access to official news, including clinical trial updates, strategic partnerships, and financial developments.
Investors and researchers will find timely updates on the company’s innovative antibody drug conjugates (ADCs) and bispecific antibody programs. Content categories include clinical milestones, regulatory filings, collaboration announcements, and manufacturing advancements.
Bookmark this page to stay informed about Sutro’s progress in developing precision oncology treatments and its role in advancing cell-free therapeutic innovation. Check regularly for verified updates directly from the company and trusted sources.
Sutro Biopharma (NASDAQ: STRO) announced the appointments of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations, enhancing its leadership team. Landa brings 20 years of regulatory experience from Amgen, while Chang has over 15 years in investor relations, previously with Solebury Trout. CEO Bill Newell and CMO Arturo Molina highlighted these appointments as vital for advancing Sutro's clinical pipeline and public presence. Sutro continues to focus on oncology therapeutics with promising products in development, including STRO-001 and STRO-002.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in four virtual conferences scheduled from November to December 2020. Key details include:
- Stifel Virtual Healthcare Conference: Nov. 16, at 3:20 PM ET.
- Jefferies Virtual London Healthcare Conference: Nov. 19, at 12:35 PM ET.
- Piper Sandler 32nd Annual Healthcare Conference: Dec. 1-3, with discussions available from Nov. 23.
- Evercore ISI HealthCONx Conference: Dec. 3, at 10:30 AM ET.
Webcasts will be available through the company’s Investor Relations website.
Sutro Biopharma reported its Q3 2020 financial results, highlighting a revenue of $17.8 million for the quarter, up from $12.3 million in Q3 2019. Total cash and marketable securities reached $202.4 million, a significant increase from $133.5 million at the end of 2019. The company is advancing its clinical trials for STRO-001 and STRO-002, with positive interim data presented at recent conferences. Sutro also recognized a $17.1 million net income, primarily from an unrealized gain on Vaxcyte common stock.
Sutro Biopharma (NASDAQ: STRO) released interim Phase 1 safety and efficacy data for STRO-002, an anti-folate receptor alpha antibody drug conjugate targeting ovarian cancer. In 34 patients analyzed, the overall response rate was 24%, with 44% of patients remaining on treatment for over 16 weeks. Results from a data cut-off of Aug. 31, 2020, indicate a disease control rate of 60% for patients treated for 12 weeks or more. The company plans to initiate a dose expansion trial in less heavily pretreated ovarian cancer patients in Q4 2020.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's presentations at two upcoming investor conferences this September. The Wells Fargo Virtual Healthcare Conference will occur on Sept. 10, 2020, at 2:00 p.m. EDT, while the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for Sept. 15, 2020, at 11:20 a.m. EDT. Webcasts of both events will be available on Sutro's website, with archived replays accessible for 30 days post-event. Sutro is focused on developing next-generation oncology therapeutics through innovative protein engineering.
Sutro Biopharma (NASDAQ: STRO) announced a conference call on September 9, 2020, to discuss updated Phase I data for STRO-002, an antibody-drug conjugate targeting ovarian and endometrial cancer. Key executives, including CEO Bill Newell and CMO Arturo Molina, will participate. The company will also present findings at the 2020 IGCS Annual Global Meeting from September 10-13, 2020, and a virtual presentation at the World ADC Digital conference from September 15-18, 2020. Intermediary results are expected to highlight STRO-002's efficacy.
Sutro Biopharma (NASDAQ: STRO) has achieved a significant milestone by delivering GMP clinical trial supply for its bispecific antibody drug conjugate (ADC), M1231, to Merck KGaA. This marks the company's first milestone payment under its 2014 collaboration with Merck. M1231 targets both MUC1 and EGFR and aims to provide innovative treatment options for solid tumors. Sutro continues to leverage its XpressCF® and XpressCF+™ technologies for drug development, reinforcing its commitment to enhance therapeutic windows for cancer patients.
Sutro Biopharma (NASDAQ: STRO) announced the promotions of Carlos Lugo to Vice President of Quality and CMC Regulatory Operations, and Devendra Luhar to Vice President of Manufacturing & Plant Operations. Lugo brings over 25 years of experience, having previously held leadership roles at Bayer and Merck, while Luhar has more than 30 years in biotech operations with experience at companies like Novartis. These changes reflect Sutro's commitment to advancing its oncology therapeutics and enhancing its cGMP manufacturing capabilities.
Sutro Biopharma (NASDAQ: STRO) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 11:30 a.m. EDT. CEO Bill Newell will lead the presentation, which can be accessed via the company’s Investor Relations page. Sutro focuses on oncology therapeutics utilizing advanced protein engineering. Notable candidates include STRO-001 and STRO-002, both in Phase 1 trials for multiple myeloma and ovarian/endometrial cancers, respectively. Sutro's innovative platforms, XpressCF® and XpressCF+™, support its mission to enhance cancer treatment.
FAQ
What is the current stock price of Sutro Biopharma (STRO)?
What is the market cap of Sutro Biopharma (STRO)?
